Lilly Plans to Submit New Drug Application for Once-Weekly Insulin Efsitora Alfa in Adults with Type 2 Diabetes by Year-End

Gelonghui June 23 | Eli Lilly announced on June 22 the detailed results of three Phase 3 clinical studies: QWINT-1, QWINT-3, and QWINT-4. These studies evaluated the efficacy and safety of once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes (T2DM): those initiating insulin therapy for the first time, those previously using daily basal insulin, and those previously using a combination of basal and mealtime insulin. All studies met their primary endpoints, demonstrating that once-weekly efsitora was non-inferior to once-daily basal insulin in reducing glycated hemoglobin (A1C) levels. Eli Lilly plans to submit a marketing application for efsitora to treat adult patients with type 2 diabetes to global regulatory authorities by the end of this year.